{"name":"Gesynta Pharma AB","slug":"gesynta-pharma-ab","ticker":"","exchange":"","domain":"gesyntapharmaab.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GS-248","genericName":"GS-248","slug":"gs-248","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"GS-248","genericName":"GS-248","slug":"gs-248","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPLWdMNFFJdl9wMmUzTjNBRzJUd1A4MHNVNnpIRTJNdlNMLWtHRld4VlY0QlJuNk43QXF0RWR1Sld5X2pxbGJ4WEI3S3FFTEJnNU13YklrS3VEeHpSTEpmLW9oZ0tBTEpaZDRJc3h6YjB3QVpEcHd0M3R5OEpwZE5JWHpRYmlfeHJsdUVMYWNyNzF1M21sTDZVUGVHODBZc2VIWEpvM2dB?oc=5","date":"2026-03-26","type":"trial","source":"Pf Media","summary":"First patient dosed in Gesynta Pharma’s endometriosis trial of vipoglanstat - Pf Media","headline":"First patient dosed in Gesynta Pharma’s endometriosis trial of vipoglanstat","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxPTkRheG11dFNObS1SUFVwcXJXQ1M0QVJpVk1JX2k4VHVKMEJzQTBjQk9GQ0tScWNwUEowXzg0Y3lEQjJKUTlYdjY2Nmd3SUZzVnJSTVk2RmhKSy1oWFk1ZHBIaEQxWU5HRHhFeE15THFwSC1FVmxXZVVuNlZjdWlyMEx6R2dhWXFxalNZRU1fWWNUNENwQmlXanFmcE1yV29lT1EzVmV0ZHFJNzVOQ1ZSaG9lQnVkUEFtS1k4dFQ2bEJoaUwyTUNkWUI2eXFkT1NoMGJLeFhObUlyN04zMUVicTYzSmpYa1FJNC01blBVZGNsTlhMM2lyUzI4SVBjekVwZmNwUWxHUHRVbnB1UnRHdENvS1drSTNkdHpRYkJrSWlPamZmZ2g0d3N3?oc=5","date":"2026-03-12","type":"pipeline","source":"PR Newswire","summary":"Endometriosis Market Expected to Achieve Significant CAGR During the Forecast Period (2026-2036) Driven by Innovative Treatment Options | DelveInsight - PR Newswire","headline":"Endometriosis Market Expected to Achieve Significant CAGR During the Forecast Period (2026-2036) Driven by Innovative Tr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxPVzA4RksxZlZJNU9QMVRGYXJRekpLUk5Jb3h6Mzk3UDFPem9zSUtzd2RSQllHbDF3LUdjbEJfYWd3UGV2UmhyT2trQWNfUlR5ZDVLVnlXYXB5czFwVG1mRDEyQWhzNEdac2hCWEk4RDl3aGxSMnpVdTA5U1BrSFBmaGZ1cnZ0MVpNVDktZF9xV0J3ZGRIQk1hbUNKZDJMVlNiUTN5Z0NsWGI5U0ZINnJxNnhWaVpocC1kTHdDWnk1Zl9IemhFQWZsbTZkM0FiaC1YZW1YekxOOHBpRWFWbG55MUQ0bXZCd1p3LS01NDg5cXFoY2Q0M3NrUk9yVjQ2YUlDaUhpeFN2b0loaWhiWW44MmdJTEdNTWtFSFNTemNYTkNEekZkWWc?oc=5","date":"2026-01-22","type":"trial","source":"GlobeNewswire","summary":"Endometriosis Clinical Trial Pipeline Accelerates as 18+ - GlobeNewswire","headline":"Endometriosis Clinical Trial Pipeline Accelerates as 18+","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQdVVwd3NrR3NfaGRYWWxVY3VleXZOX2lEQmRtYWJ5Zmw5Nnh0UEkwbmJTNEM3YlNrLXMwd2pEbExSNXBvSEU3UkI3ejR5eWg4a3JtRWhrVjlqX2wzZjJZdmF6c2hPZzdCTEhyRmQwNUtWRU5lOFR4SDBDU0c1aTdxUVZmTWwtbFBKZk85OENlbDlTZFpreGJCSk5YcW5uelg0eWFOdVEwbkdvZ0RlUVRQdllaeVZobjV6N0VJV3F2NnUzUQ?oc=5","date":"2025-09-30","type":"regulatory","source":"beQuoted","summary":"Gesynta Pharma receives UK approval for a Phase 2 trial of vipoglanstat in endometriosis - beQuoted","headline":"Gesynta Pharma receives UK approval for a Phase 2 trial of vipoglanstat in endometriosis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPaEY4dElMOEVua3ZtSDhSY2p4aXJsWFoxYXJNb0M0RTk1VnFrNTZRcGJUWjhySGNSTGk5SHNnbVRQWlFoWEZJc1U4bVExY1YwMlB6bU9tX3RURWdLM3JWREVJU0tnaE42Z2drN3VLVVpDbDdpWmJlMzVuQ2V3Mm5ZNXppZEdLYjZoYXFlSkJfbW9ESU12Q0pFc3R0YTRMNDI3b3I5UDdhLXl2TE1OcTRWTnhtZEZnZ1JiRUlZX2FrME41c1k?oc=5","date":"2025-02-13","type":"pipeline","source":"Forbes","summary":"Gesynta Pharma Receives $27 M For Endometriosis Novel Therapy Drug - Forbes","headline":"Gesynta Pharma Receives $27 M For Endometriosis Novel Therapy Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOLXFMV2ViUWI1TmZpZVMtMm1mXzc2dlBuNUgzRTNiSWJGeXFncllEYkpMc1VscC12MkZyaDVhcTNEcnpqNXh0MFVsSmF0X0JpNkpOYjJCVUtLa0U5RnlYTUlKOFplTUhOWmxZRlRWeWZtc2txZG4wem9TN3o1UE14S1NaV3h1bW91UHRybTZ5ckdhZ0lLU1Z4bTg1WVlRMEp1R0hMWjFTdkIyZDFJMGdrS1F5LUVyajR2OGxWOEVkRnZUUQ?oc=5","date":"2023-08-24","type":"regulatory","source":"beQuoted","summary":"Gesynta Pharma's drug candidate GS-073 approved for clinical development in chronic inflammatory pain - beQuoted","headline":"Gesynta Pharma's drug candidate GS-073 approved for clinical development in chronic inflammatory pain","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOYTZERER1TUhfMWNuNHRyczVUTUw4VklPcERwYWloaTh5cDl6VVFsTFNub1R1NldIUXFVOVhhU3JzenVIaUg2VTNMUFF0VGxuc2NvVzB1RFJrNVVJaUp6aUgzMUUyZGtreXZGdzlLcDNUNUtIaHp4aDE1ZzZEVzliNnhRU0lOaHFqVWMxNmZ2ZTFCbS15M0FQN0ZPSFJHUEFycllEbDNfTFZxUHRsN3VmUGVVTUg?oc=5","date":"2022-09-08","type":"pipeline","source":"BioWorld News","summary":"Gesynta Pharma presents mPGES1 inhibitor GS-248 for pain and inflammation - BioWorld News","headline":"Gesynta Pharma presents mPGES1 inhibitor GS-248 for pain and inflammation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPclZla1ByZk1TTlUwd0hHUE43U1JhcjJBcVVZLU9GOXRwaVUwZnV0cjAyTkdZNzRkcmU2Yld5Ri16RGdfdVhyTno0bzNKLWdmSEFJWVlYVTN1d1paS1ZlNnp0ckNYejItbVI3b1dUY1oxTjQtdXVYX2pwdGdWeUhWOTlPdkpGN3FzRkNXb2hFeXU0Nzk5R3JldXhIMWpvVnJvWFhFTnhieXM?oc=5","date":"2020-07-08","type":"pipeline","source":"BioWorld News","summary":"Gesynta raises $21M to test novel mechanism in systemic sclerosis - BioWorld News","headline":"Gesynta raises $21M to test novel mechanism in systemic sclerosis","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}